1988 The Institute of Contemporary 

Biochemical Technology was established 1993 The Wuhan Contemporary High-tech Industry Co., LTD was established (Later renamed as Humanwell Technology - Humanwell Healthcare)

1996 The Wuhan Yangzijiang Biochemical Pharmaceutical Factory was merged (Later renamed as Wuhan Humanwell)

1997 Listed on Shanghai Stock Exchange

1998 Raise the goal of "creating a century-old enterprise" and establish the mission and cultural system of "Keep the Tree of Life Green”

2001 Establish Yichang Humanwell Pharmaceutical Co., Ltd, Gedian Humanwell Pharmaceutical Co., Ltd and Xinjiang Uyghur Pharmaceutical Co., Ltd.

2006 Raise the strategy of "Leading the Pharmaceutical Market Segments”, clarify the development model and path of the company, which is transforming from the extended expansion to the connotative growth, and from the opportunity-oriented to the strategy-oriented pathway.

2008 Humanwell Healthcare Research Institute was established to fully integrate the group's R&D resources

2009 Officially start the path of international development the company expanded its business in Africa, and established Humanwell Pharma Mali S.A. At the same time, the company expanded its business in USA, and established Wuhan PuraCap and American PuraCap.

2011 Humanwell Healthcare settled in Biolake, and the construction of Biolake Industrial Park began

2015 Humanwell's African pharmaceutical factory area was constructed and put into operation Yichang Humanwell Production Base for export was constructed and put into operation

2017 Humanwell Pharmaceutical Ethiopia PLC was constructed and put into operation. It is the first manufacturing facility in Ethiopia invested and constructed by Hubei enterprise.

2018 Implement the strategy of "recentering”

2019 The business revenue exceeded 20 billion CNY

The new chemical Category 1 drug, Remazolam Besylate for Injection was approved for listing. It is the first new chemical Category 1 drug in Hubei Province, breaking the streak of no innovative drugs listed in the domestic and international field of sedation for nearly 30 years.

The construction of the global headquarters for Yichang Humanwell started.

The new chemical Category 1 drug, fospropofol disodium for injection was approved for listing. It is the first prodrug of propofol in China and one of the most advanced systemic intravenous anesthetics studied at home and abroad.

Huanggang Humanwell started construction, providing a strong guarantee for the modern production of globally used raw material products including innovative drugs, characteristic drugs, and drugs in short supply.

The new TCM Category 1 drug, Snowbellleaf Tickclover General Flavone Capsule was approved for listing. It becomes the world's first new TCM drug indicated for the prevention and treatment of urinary calculi.

Clobazam of Yichang Humanwell was approved for listing, which was the company's first foray into the field of rare diseases.

The first modified complex high-end injection RF16001 of Yichang Humanwell was approved for clinical use, a breakthrough in the research and development of complex high-end new drugs.

The Category 1 new drug, RFUS-144 Injection of Yichang Humanwell was approved for clinical use.

Yichang Humanwell was awarded with the second prize of the 18th Science and Technology Award by the Chinese Pharmaceutical Association, and the third prize in the finals of the China Innovation Method Competition.

Wuhan Humanwell won the title of “Little Giant” firm for national specialized and sophisticated enterprises that produce new and unique products.

Xinjiang Uyghur Pharmaceutical Co., Ltd won the special prize of 2023 Science and Technology Progress Award by China Ethnic Medicine Association.

The Category 1 new drug, LL-50 Injection of Yichang Humanwell was approved for clinical use.